Interactive data exploration and analysis is an inherently personal process. One's background, experience, interests, cognitive style, personality, and other sociotechnical factors often shape such a process, as well as the provenance of exploring, analyzing, and interpreting data. This Viewpoint posits both what personal information and how such personal information could be taken into account to design more effective visual analytic systems, a valuable and under-explored direction.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1109/MCG.2020.2982465 | DOI Listing |
J Nepal Health Res Counc
March 2024
Star Hospital, Lalitpur, Nepal.
N/A.
View Article and Find Full Text PDFR I Med J (2013)
December 2021
Lead, Outbreak Teams in RIDOH's COVID-19 Epi-Ops Unit.
The COVID-19 pandemic has impacted certain workplace settings disproportionately, putting some industries at a higher risk for workplace transmission than others. This study examines workplace clusters in Rhode Island between March 2020 and May 2021. There were 14,580 cases associated with 2784 clusters during this period, with the largest number of workplace clusters occurring in manufacturing, food services, and retail.
View Article and Find Full Text PDFR I Med J (2013)
October 2017
Associate Professor of Medicine, Warren Alpert Medical School of Brown University, Providence, RI.
[Full article available at http://rimed.org/rimedicaljournal-2017-10.asp].
View Article and Find Full Text PDFRoss Fiziol Zh Im I M Sechenova
May 2014
The review is devoted to the widely discussed problems of the feasibility of "systems biology" and "P4-personalized (systems) medicine" from the standpoint of complex living systems. The following conclusions are made. 1.
View Article and Find Full Text PDFAnn Health Law
June 2012
University of Maryland School of Law, Baltimore, MD, USA.
The idea that genetic information is different from other medical information and therefore needs special protection has led to a regulatory puzzle where genetic testing is currently regulated under three separate schemes. Although genetic tests for over 2,000 diseases are available, less than 10% of these tests have been reviewed for clinical validity or utility. Recent action by some genetic testing companies has prompted the federal government to propose changes to the current regulatory scheme.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!